Asymptomatic paroxysmal atrial fibrillation (AF) is often found in patients implanted with cardiac implantable electronic devices (CIEDs). Second-generation atrial antitachycardia pacing (A-ATP) is effective in managing AF in patients implanted with CIEDs. The purpose of this study was to evaluate the efficacy and safety of A-ATP in patients implanted with CIEDs. This was a single-center retrospective study involving 91 patients (male 46 patients, mean age 74 ± 9 years) implanted with Reactive A-ATP equipped devices (84 patients with pacemakers, 6 with ICDs, and 1 with a CRT-D). The AF burden, rate of AF termination, and details of the activation of the A-ATP were analyzed in each patient. During a mean follow-up period of 21 ± 13 months, A-ATP was activated in 45 of 91 patients (49.5
BACKGROUND:The impact of the starting dose of tyrosine kinase inhibitors (TKIs) following combination therapy of immune checkpoint inhibitors with TKIs (i.e. IO-TKI) for advanced renal cell carcinoma (RCC) remains unclear. METHODS:We retrospectively evaluated clinical data from 155 patients treated with first-line IO-TKI for RCC. Patients were categorized into full-dose and reduced-dose groups based on their starting dose of TKIs. Effectiveness and safety profiles were compared between groups. RESULTS:A reduced starting dose was administered to 52 patients (34%). These patients were older (P = 0.0137) and received pembrolizumab plus axitinib more frequently, while lenvatinib plus pembrolizumab was less used (P = 0.0258) compared to the full-dose group. Progression-free survival and overall survival did not significantly differ between the full-dose and reduced-dose groups (P = 0.202 and P = 0.309, respectively). Although the objective response rate appeared higher in the full-dose group, the difference was not statistically significant after adjusting for other covariates (P = 0.0588). Safety profiles were comparable, with no significant differences in TKI dose reduction, drug interruption or discontinuation, or glucocorticoids use (P > 0.05). However, adverse events of grade ≥3 were more frequent in the full-dose group, although not statistically significant (P = 0.121). CONCLUSION:The starting dose of TKIs did not significantly impact clinical outcomes following IO-TKI for RCC. These findings suggest a potential for the optimization of the starting dose of TKIs; however, prospective studies are warranted to confirm these findings.
BACKGROUND:Early oral intake (EOI) is a core component of Enhanced Recovery After Surgery (ERAS) protocols. Although EOI after gastrectomy has been shown to improve recovery and reduce postoperative complications, its real-world implementation across Japan remains unclear. This study aimed to evaluate the current status and institutional factors influencing EOI after gastric cancer surgery using a nationwide database. METHODS:This retrospective observational study used Japan's nationwide Diagnosis Procedure Combination (DPC) database to analyze 26,097 patients who underwent gastric cancer surgery at 472 institutions from 2017 to 2022. Patients were divided into EOI and non-EOI groups based on oral intake initiation within two days postoperatively. Surgical methods, hospital characteristics, and length of stay were compared. RESULTS:Only 20.8 % of patients initiated EOI. Laparoscopic distal gastrectomy had significantly higher EOI rates compared to open procedures. However, no significant difference was observed for proximal or total gastrectomy. Larger hospitals and designated cancer centers showed higher EOI rates. The EOI group had a significantly shorter postoperative stay (median 9 vs. 12 days, p < 0.001). CONCLUSIONS:EOI following gastrectomy is associated with shorter hospitalization, yet its adoption remains low in Japan. Institutional factors and multidisciplinary collaboration may play crucial roles in promoting EOI. Findings may inform perioperative optimization and ERAS standardization in oncologic gastric surgery.
Abstract Background Outcomes of catheter ablation for persistent atrial fibrillation (AF) remain suboptimal despite durable pulmonary vein isolation (PVI). Dominant frequency (DF) mapping has been proposed to identify AF-maintaining drivers, yet its incremental value beyond PVI has not been tested in a multicenter randomized trial. The relative importance of functional high-frequency activity versus structural remodeling in determining recurrence remains unclear. Purpose To evaluate whether DF-guided ablation improves outcomes after PVI and to define the mechanistic hierarchy between functional frequency domains and structural substrate in persistent AF. Methods PAD-AF was a prospective, investigator-initiated, multicenter randomized trial conducted at six centers. Patients undergoing first ablation for persistent or long-standing persistent AF were enrolled. After successful PVI, bi-atrial high-density mapping with fast Fourier transform analysis was performed during ongoing AF. High-DF sites were defined as ≥7 Hz with regularity index ≥0.2. Patients with high-DF sites were randomized 1:1 to adjunctive DF ablation or PVI alone. Patients without high-DF sites formed a predefined exploratory cohort. Low-voltage areas (LVAs; <0.5 mV) were quantified during sinus rhythm. The primary endpoint was freedom from AF recurrence (>30 s) off antiarrhythmic drugs at 12 months after a single procedure. Results A total of 103 patients were enrolled; 64 with high-DF sites were randomized (DF n=32; PVI n=32), and 39 had no high-DF sites. AF-free survival off antiarrhythmic drugs at 12 months was 81.3% in the DF group versus 68.9% in the PVI group (P=0.228). Freedom from any atrial arrhythmia was 78.1% versus 65.6% (P=0.263). Patients without high-DF sites demonstrated the most favorable outcome (83.3%; P=0.065 vs PVI), identifying absence of high-frequency activity as a favorable substrate phenotype. High-DF sites showed minimal spatial concordance with LVAs (LA overlap 9–19%; RA 3–6%), indicating functional–structural dissociation. In multivariable analysis, right atrial LVA burden independently predicted recurrence (HR 1.031 per 1% increase; 95% CI 1.005–1.058; P=0.018), whereas DF ablation did not. No major complications occurred. Conclusion Adjunctive DF-guided ablation did not significantly improve outcomes beyond PVI. Right atrial structural remodeling—not frequency-defined drivers—emerged as the dominant determinant of recurrence, redefining the mechanistic hierarchy of substrate relevance in persistent AF. These findings represent a paradigm shift, suggesting that frequency mapping may serve primarily for substrate stratification rather than empirical ablation and highlighting right atrial remodeling as a key target in the era of pulsed field ablation.Voltage mapping and ablation lesion sets